These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2018-002653-29||Multicenter, randomized, dose-finding, parallel, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of intramuscular administration of allogeneic mesenchymal cells deriv...||not-yet-due|
|Ongoing||2019-002873-80||Unicentre, open, uncontrolled clinical trial to assess the morphological, biochemical and functional effects of Diflunisal treatment in patients with transthyretin cardiac amyloidosis Ensayo clínic...||not-yet-due|
|Ongoing||2019-003101-97||An unicentric, open, randomized and crossover clinical trial to evaluate vitamin D supplementation effect of colecalciferol versus calcidiol in mineral metabolism in hemodialisis patients. Ensayo...||not-yet-due|
|Ongoing||2019-004637-16||Pilot, single-center, non-comparative clinical trial to assess the safety and preliminary efficacy of the administration of adipose tissue-derived MSCs (MSCs-TA) injected at the edges of the ulcer and...||not-yet-due|
|Ongoing||2019-004871-38||Phase IV, single-center, open study to assess the benefits of the start of immediate treatment without immunovirological data (“Same Day Treatment”) compared to conventional treatment with BIC / FTC /...||not-yet-due|
|Ongoing||2021-001560-14||Single-center, open-label, uncontrolled clinical trial to evaluate the association between the expression of the JAK / STAT pathway and the response to tofacitinib in patients with refractory rheumato...||not-yet-due|
|Ongoing||2021-005486-40||Phase IIa multicenter clinical trial to determine the feasibility and safety of the use of adipose-derived mesenchymal stem cells (ASC) in the treatment of patients with cicatricial conjunctivitis ass...||not-yet-due|
|Ongoing||2021-006068-26||CLINICAL TRIAL PHASE IIa TO EVALUATE THE SAFETY AND EFFECTIVENESS OF TREATMENT WITH FAT-DERIVED MESENCHYMAL ALLOGENIC MESENCHYMAL TRONCAL CELLS IN PATIENTS WITH SINGLE INFLAMMATORY STENOSIS IN THE CON...||not-yet-due|